Science

DENVER, CO -November 28, 2018 /AxisWire/ Nexien BioPharma Inc. (OTC QB: NXEN)  (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral cannabinoid formulations developed by Nexien,...

Denver, Colorado, November 5, 2018 /AxisWire/ Nexien BioPharma Inc. (OTC QB: NXEN)  (“Nexien” or the “Company”) announced that it was initiating an investigation into the use of cannabinoid-based formulations for the treatment of patients suffering from Myotonic Dystrophy (DM) and...